In today’s world of Orthopedic Biomaterials, one thing that is expanding rapidly is the amount of new products in the research pipeline: stem cells, bone growth factors, gene therapy, synthetic bone fillers, bioactive implant coatings and biopolymers among others. The overall market is expected to enjoy healthy growth over the next 5 years, but the number one expansion story is in the bone growth factors and proteins segment, so called orthobiologics. These products could grow from just a few percent of the orthopedic biomaterials market in 2002 to as much as 25-30% of the market by 2007. This product segment also brings many new players to the market, namely pharmaceutical and biotech companies.
The leading orthopedic companies are focused on what they do well, high-quality manufacturing and professional marketing and sales to increase market share and penetration. However, to be successful, they need a strong pipeline of new technology and products, the very ingredients that the biotech industry brings to the table. But for their part, the biotech industry and small orthopedic technology companies don’t have the market presence or dedicated marketing and sales force to effectively compete with the leaders in the orthopaedic industry. The two sectors need each other.
This comprehensive report examines the major factors in shaping the industry as we move toward the future. Understanding the driving clinical, technological, regulatory, and business factors will be crucial in strategic decisions about partners and markets, and for successful product commercialization.
The report covers two main market segments, and their respective sub-markets: (1) Bone Repair and Replacement, including Structural Bone Grafts, Bone Fillers, Implant Coatings, and Bone Growth Factors; and (2) Soft Tissue Repair, including Tissue Grafts, Tissue Regeneration, Knee Ligament Fixation Devices, Meniscal Repair Devices, Shoulder Repair Devices, Synovial Fluid Replacement. Each section includes a look at the technologies and worldwide markets in 2002, as well as forecasts for the markets and new products through 2007.